Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc has demonstrated a strong potential for growth due to its investigational drug assets targeting Alzheimer's disease, including promising results from preclinical studies of IGC-AD1. The company’s current valuation is considered attractive, supported by an upward adjustment to its 12-month price target, indicating significant upside potential based on net present value analysis. Furthermore, the anticipation of positive data and progress in ongoing research is likely to act as a catalyst for future stock performance.

Bears say

IGC Pharma Inc. reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(0.02), which aligns with previous estimates but indicates ongoing financial challenges. The company faces significant risks, including balance sheet and liquidity issues, the potential failure of its investigational drug candidates in demonstrating safety and efficacy, and hurdles in obtaining regulatory approvals. Additionally, the competitive landscape and shifting investor sentiment towards biotech stocks further exacerbate uncertainties surrounding IGC Pharma's future performance and market position.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.